You are here: Geisinger Medical
Laboratories > Test
Catalog
Geisinger Medical Laboratories Test Catalog
MYELIN OLIGODENDROCYTE GLYCOPROTEIN (MOG) ANTIBODY WITH REFLEX TO TITER, SERUM |
||
Geisinger Epic Procedure Code: LAB1080
Geisinger Epic ID: 52245
|
||
SPECIMEN COLLECTION |
||
Specimen type: |
Serum | |
Preferred collection container: |
||
Specimen required: |
2 mL serum; minimum 0.5 mL | |
Special notes: |
Serum separator tube unacceptable. | |
| SPECIMEN PROCESSING |
||
Specimen processing instructions: |
Centrifuge and aliquot. | |
Transport temperature: |
Refrigerated (cold packs). | |
Specimen stability: |
Room temperature: 7 days. Refrigerated: 14 days. Frozen: 21 days. | |
Rejection criteria: |
Serum Separator Tube (SST) • Visible particulate matter | |
TEST DETAILS |
||
CPT code(s): |
86362 | |
| Note: The billing party has sole responsibility for CPT coding. Any questions regarding coding should be directed to the payer being billed. The CPT codes provided by GML are based on AMA guidelines and are for informational purposes only. | ||
Test includes: |
If the MOG Antibody screen is positive, then a semi-quantitative titer will be performed at an additional charge (CPT code(s): 86256). | |
Methodology: |
Cell-based Immunofluorescence Assay |
|
Synonyms: |
Quest test code 36952, MOG AB Ser
|
|
Clinical significance: |
Neuromyelitis optica (NMO) is an inflammatory disorder predominantly affecting the optic nerves and spinal cord. Limited forms of disease including isolated optic neuritis, brainstem encephalitis and longitudinal extensive transverse myelitis (LETM) or acute disseminated encephalomyelitis (ADEM) have been referred to as NMO spectrum disorder (NMOSD). The majority of individuals with NMO and many with NMOSD have antibodies against aquaporin 4 (AQP4). MOG antibodies have been reported without AQP4 antibodies in individuals with NMO and other non-multiple sclerosis demyelinating diseases. The presence of MOG antibodies in AQP4 antibody negative individuals can help differentiate between multiple sclerosis (MS) and non-MS demyelinating diseases and aid in clinical management decisions. | |